查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1699344

連網藥物輸送設備市場機會、成長動力、產業趨勢分析及 2025-2034 年預測

Connected Drug Delivery Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球連網藥物輸送設備市場價值為 4.912 億美元，預計 2025 年至 2034 年期間將以 31.8% 的強勁複合年成長率擴張。這些設備整合了藍牙、Wi-Fi 和物聯網 (IoT) 等現代技術，以改善藥物管理和管理。它們包括智慧吸入器、胰島素筆、穿戴式注射器和智慧藥丸分配器，旨在監測藥物使用、增強依從性並實現患者和醫療保健提供者之間的即時溝通。氣喘、糖尿病和心血管疾病等慢性病的發病率上升，推動了對這些先進藥物傳遞系統的需求。藥物依從性差是醫療保健領域的一個長期存在的問題，導致醫療成本增加和病患治療效果不佳。連網藥物輸送設備可確保適當的藥物攝取、簡化疾病管理和減少醫院就診次數，從而幫助解決這些問題。

連網藥物傳輸設備市場 - IMG1

根據設備類型，市場分為連接感測器和整合設備。 2024 年，整合設備佔據了最大的收入佔有率，為 60.9%。這些設備配備了提醒、追蹤功能和即時數據共享功能，顯著提高了患者對治療計劃的依從性。遠端監控藥物攝取的能力加強了其在醫療保健環境中的採用。慢性病的日益普及進一步擴大了對綜合藥物輸送解決方案的需求。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 4.912億美元
預測值 72.5億美元
複合年成長率 31.8%

根據技術，市場分為藍牙、近場通訊和 Wi-Fi。 2024 年，藍牙領域的收入佔有率最高，為 47.7%。低功耗、經濟實惠以及與行動健康應用的無縫整合推動了支援藍牙的藥物輸送設備的廣泛應用。這些設備促進了患者和醫療保健提供者之間的即時資料交換，支援遠端監控和數位健康平台。隨著慢性病發病率的上升，支援藍牙的智慧吸入器、胰島素筆和自動注射器的需求正在增加。此外，製藥和醫療科技公司對藍牙為基礎的生物感測器和穿戴式注射器的投資不斷增加，正在加強市場擴張。

根據應用，市場分為過敏反應、呼吸系統、心血管、糖尿病、荷爾蒙替代和其他用途。 2024 年，呼吸系統疾病領域創造了 2.21 億美元的最高收入。氣喘、慢性阻塞性肺病 (COPD) 和其他呼吸系統疾病的負擔日益加重，增加了對連網藥物輸送解決方案的需求。這些設備不僅提高了治療依從性，還支援遠端患者監控，加強了遠距醫療服務的擴展。

根據最終用途，市場也細分為醫院、診所、家庭護理機構等。家庭護理領域在 2024 年的收入達到 1.985 億美元，居家護理領域佔據領先地位。由於人口老化和慢性病管理需求的不斷成長，人們對家庭醫療保健的偏好日益成長，這刺激了對連網藥物輸送系統的需求。這些設備支援自我管理和遠端監控，使患者能夠更有效地管理自己的病情。

美國連網藥物輸送設備市場規模預計將從 2023 年的 1.56 億美元大幅成長至 2034 年的 27 億美元。遠距醫療服務的日益普及，尤其是在 COVID-19 疫情之後，加速了用於遠距醫療監控的連網設備的部署。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 提高患者對遵守處方治療的認知
      • 快速發展的醫療保健IT基礎設施
      • 機器學習和人工智慧的採用率飆升
      • 整合 AR/VR 技術的遠距醫療平台應用日益增多
    • 產業陷阱與挑戰
      • 有關患者資料的安全問題
      • 設備價格高
  • 成長潛力分析
  • 監管格局
  • 技術格局
  • 未來市場趨勢
  • 差距分析
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 策略儀表板

第5章：市場估計與預測：按設備類型，2021 年至 2034 年

  • 主要趨勢
  • 連接的感測器
    • 連接的吸入感測器
    • 連接注射感測器
  • 整合設備
    • 整合吸入裝置
    • 整合注射裝置

第6章：市場估計與預測：按技術，2021 年至 2034 年

  • 主要趨勢
  • 藍牙
  • 近場通訊
  • 無線上網

第7章：市場估計與預測：按應用，2021 年至 2034 年

  • 主要趨勢
  • 過敏反應
  • 呼吸系統
  • 心血管
  • 糖尿病
  • 荷爾蒙替代
  • 其他應用

第8章：市場估計與預測：依最終用途，2021 年至 2034 年

  • 主要趨勢
  • 醫院
  • 診所
  • 居家照護環境
  • 其他最終用途

第9章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 波蘭
    • 瑞士
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 印尼
    • 越南
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 秘魯
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列

第10章：公司簡介

  • Adherium
  • Aptar Pharma
  • AstraZeneca
  • Becton, Dickinson, and Company
  • Bigfoot Biomedical
  • Cohero Health
  • Eli Lilly and Company
  • Insulet Corporation
  • Novartis
  • Novo Nordisk
  • Phillips Medisize
  • Propeller Health
  • Teva Pharmaceuticals
  • West Pharmaceutical Services
  • Ypsomed
簡介目錄
Product Code: 4422

The Global Connected Drug Delivery Devices Market was valued at USD 491.2 million in 2024 and is anticipated to expand at a robust CAGR of 31.8% from 2025 to 2034. These devices integrate modern technology, such as Bluetooth, Wi-Fi, and the Internet of Things (IoT), to improve medication management and administration. They include smart inhalers, insulin pens, wearable injectors, and intelligent pill dispensers, all designed to monitor medication usage, enhance adherence, and enable real-time communication between patients and healthcare providers. The rising incidence of chronic conditions, including asthma, diabetes, and cardiovascular diseases, is fueling demand for these advanced drug delivery systems. Poor medication adherence is a persistent issue in healthcare, leading to higher costs and suboptimal patient outcomes. Connected drug delivery devices help address these concerns by ensuring proper medication intake, streamlining disease management, and reducing hospital visits.

Connected Drug Delivery Devices Market - IMG1

The market is segmented based on device type into connected sensors and integrated devices. Integrated devices accounted for the largest revenue share of 60.9% in 2024. These devices, equipped with reminders, tracking features, and real-time data-sharing capabilities, significantly improve patient compliance with treatment plans. The ability to monitor medication intake remotely has strengthened their adoption across healthcare settings. The increasing prevalence of chronic illnesses has further amplified the demand for integrated drug delivery solutions.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$491.2 Million
Forecast Value$ 7.25 Billion
CAGR31.8%

Based on technology, the market is divided into Bluetooth, near field communication, and Wi-Fi. The Bluetooth segment held the highest revenue share of 47.7% in 2024. Low power consumption, affordability, and seamless integration with mobile health applications have driven the widespread adoption of Bluetooth-enabled drug delivery devices. These devices facilitate real-time data exchange between patients and healthcare providers, supporting remote monitoring and digital health platforms. With the rising incidence of chronic diseases, Bluetooth-enabled smart inhalers, insulin pens, and autoinjectors are witnessing increased demand. Additionally, growing investments by pharmaceutical and MedTech companies in Bluetooth-based biosensors and wearable injectors are strengthening market expansion.

By application, the market is categorized into anaphylaxis, respiratory, cardiovascular, diabetes, hormone replacement, and other uses. The respiratory segment generated the highest revenue of USD 221 million in 2024. The increasing burden of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders has amplified the need for connected drug delivery solutions. These devices not only improve treatment adherence but also support remote patient monitoring, strengthening the expansion of telehealth services.

The market is also segmented by end use into hospitals, clinics, home care settings, and others. The home care segment led with USD 198.5 million in revenue in 2024. The growing preference for home-based healthcare, driven by an aging population and the rising need for chronic disease management, has fueled demand for connected drug delivery systems. These devices enable self-administration and remote monitoring, allowing patients to manage their conditions more efficiently.

The U.S. connected drug delivery devices market is projected to grow significantly from USD 156 million in 2023 to USD 2.7 billion by 2034. The increasing adoption of telehealth services, particularly after the COVID-19 pandemic, has accelerated the deployment of connected devices for remote healthcare monitoring.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising patient awareness about adherence to prescribed therapies
      • 3.2.1.2 Rapidly moving healthcare IT infrastructure
      • 3.2.1.3 Soaring adoption of machine learning, and artificial intelligence
      • 3.2.1.4 Rising implementation of telehealth platform integrated with AR/VR technologies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Security concerns regarding patient data
      • 3.2.2.2 High price of devices
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Device Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Connected sensors
    • 5.2.1 Connected inhalation sensors
    • 5.2.2 Connected injectable sensors
  • 5.3 Integrated devices
    • 5.3.1 Integrated inhalation devices
    • 5.3.2 Integrated injectable devices

Chapter 6 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Bluetooth
  • 6.3 Near field communication
  • 6.4 Wi-Fi

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Anaphylaxis
  • 7.3 Respiratory
  • 7.4 Cardiovascular
  • 7.5 Diabetes
  • 7.6 Hormone replacement
  • 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Home care settings
  • 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Poland
    • 9.3.7 Switzerland
    • 9.3.8 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Thailand
    • 9.4.7 Indonesia
    • 9.4.8 Vietnam
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Columbia
    • 9.5.5 Peru
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Israel

Chapter 10 Company Profiles

  • 10.1 Adherium
  • 10.2 Aptar Pharma
  • 10.3 AstraZeneca
  • 10.4 Becton, Dickinson, and Company
  • 10.5 Bigfoot Biomedical
  • 10.6 Cohero Health
  • 10.7 Eli Lilly and Company
  • 10.8 Insulet Corporation
  • 10.9 Novartis
  • 10.10 Novo Nordisk
  • 10.11 Phillips Medisize
  • 10.12 Propeller Health
  • 10.13 Teva Pharmaceuticals
  • 10.14 West Pharmaceutical Services
  • 10.15 Ypsomed